| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T26 |
0-105 |
Sentence |
denotes |
The cross-immunity between viral antigens and peripheral nerve glycolipids have not been well-documented. |
| T27 |
106-211 |
Sentence |
denotes |
Positive GD1a antibody was reported in a few patients with dengue virus-related GBS (Simon et al., 2016). |
| T28 |
212-332 |
Sentence |
denotes |
Anti-ganglioside antibody was not found in patients with COVID-19 and Zika virus-related GBS (Cao-Lormeau et al., 2016). |
| T29 |
333-548 |
Sentence |
denotes |
This has led to speculation that the neuropathy in viral infections-related GBS could be due to other autoantibodies that are not detected as yet or the viruses produced nerve damage due to other neurotoxic effects. |
| T30 |
549-669 |
Sentence |
denotes |
However, there is paucity of evidence of direct infection of peripheral nerves by viruses from the pathological studies. |
| T31 |
670-789 |
Sentence |
denotes |
Good response to immunotherapy in viral infection-related GBS is also against the direct neurotoxic effects of viruses. |
| T32 |
790-959 |
Sentence |
denotes |
COVID-19 patients with AIDP responded better as compared to those with axonal variants of GBS; a difference also seen in patients with dengue and Zika virus-related GBS. |
| T33 |
960-1063 |
Sentence |
denotes |
Recently, a good clinical response in pneumonia has been seen in COVID-19 patients with plasma therapy. |
| T34 |
1064-1148 |
Sentence |
denotes |
Does plasma therapy produce good recovery in COVID-19-related GBS is yet to be seen. |
